His current focus is on estimating the effects of longitudinal therapies (i.e., sequences of treatment decisions made over time) in pregnant women. This population is one of the most vulnerable among us yet has the least evidence for effective therapies. Little evidence exists because randomized controlled trials are difficult to conduct in this population. Therefore, robust observational studies using cutting-edge statistical tools are critical for improving our knowledge of the best treatment strategies in these vulnerable patients.

Dr. Loop's research experience has led to several opportunities to provide outreach, including leading the writing of the Total Cardiovascular Disease chapter for the AHA/ASA statistics updates in 2021 and 2022, serving as a statistical reviewer for JAMA Network Open, an ad hoc reviewer for other journals focused on cardiovascular disease, an ad hoc reviewer for study section at NIH, and statistical consulting for individuals and organizations.